Lasa Supergenerics Limited, a vertically built-in group spanning all the animal and human healthcare worth chain has introduced its monetary outcomes for the third quarter ended December 31st 2020 (Q3FY21).
Q3FY21 efficiency overview in contrast with Q3FY20
- The Finance value lowered by 95.40% Y-o-Y from Rs. 1.6 crore in Q3FY20 to Rs. 0.07 crore in Q3FY21
- Revenues from operations stood at Rs. 53.98 crore as in opposition to Rs. 39.29 crore in Q3FY20
- EBITDA of Rs. 12.56 crore as in comparison with Rs. 8.16 crore in Q3FY20
- EBITDA margins at 23.26% as in opposition to 20.78% in Q3FY20
- PAT stood at Rs. 6.56 crore as in opposition to of Rs. 2.58 crore
- EPS for Q3FY21 stood at Rs. 1.61 as in comparison with Rs. 0.89 in Q3FY20
Q3FY21 efficiency overview in contrast with Q2FY21
- The Finance value lowered by 60% Q-o-Q from Rs. 0.19 crore in Q2FY21 to Rs. 0.07 crore in Q3FY21
- Revenues from operations stood at Rs. 53.98 crore as in opposition to Rs. 54.69 crore in Q2FY21
- EBITDA of Rs. 12.56 crore as in comparison with Rs. 12.79 crore in Q2FY21
- EBITDA margins at 23.26%
- PAT stood at Rs. 6.56 crore as in comparison with Rs. 7.05 crore in Q2FY21
- EPS for Q3FY21 stood at Rs. 1.61
Highlights For Third quarter ended December 31st 2020
Revenues from operations for the Third quarter ended December 31st, 2020 (Q3FY21) stood at Rs. 53.98 crore.
The Company reported Earnings earlier than Interest, Tax, Depreciation and Amortization (EBITDA) of Rs. 12.56 crore in Q3FY21, as in opposition to Rs. 12.79 crore in Q3FY21;
The Company’s EBITDA margin stood at 23.26%
The Company reported PAT of Rs. 6.56 crore for Q3FY21
The Company’s PAT margin stood at 12.10%
Earnings per share (EPS) for the quarter ended Q3FY21 stood at Rs. 1.61
Commenting on the efficiency, Dr. Omkar Herlekar, Chairman – Lasa Supergenerics Limited, mentioned, “We continued to deliver robust top line in these competitive market scenarios. I am glad to say that we have achieved almost Zero Finance cost in the company, we are in line with our commitments and we continue to work even harder to grow. We remain confident for achieving our objectives of driving sustainable growth in our revenue and cash flows.”
About Lasa Supergenerics Limited (www.lasalabs.com; BSE: 540702; NSE: LASA)
Incorporated in 2011, Lasa Supergenerics Limited is a globally nicely trusted model with top quality merchandise, accepted by giant corporations throughout the globe. Our Company is the pioneer and amongst the main gamers within the manufacturing of Veterinary APIs, with a well-established model identified for its high-quality merchandise amongst varied clients. The Company has its unit with state of artwork manufacturing amenities situated at Mahad & Chiplun, Maharashtra with a complete put in capability of 4,300 MT. The Company has over 25% of APIs exported to counties like Australia, Bangladesh, Middle East, China, Turkey, Egypt, Jordan, Korea, Pakistan and so forth.
